Drug updated on 11/16/2023

Dosage FormCapsule (oral: 0.25 mg, 0.5 mg, 0.75 mg, 1 mg)
Drug ClassPoly (ADP-ribose) polymerase (PARP) inhibitors
Ongoing and
Completed Studies


  • For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.

Product Monograph / Prescribing Information

Document TitleYearSource
Talzenna (talazoparib) Prescribing Information.2021Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials. 2023Cancers
Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis. 2023European Oncology Urology
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: a meta-analysis and GRADE recommendations by the italian association of medical oncology.2022The Breast
Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. 2022PLoS One
Comparative safety and tolerability of approved PARP inhibitors in cancer: a systematic review and network meta-analysis.2021Pharmacological Research
PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.2021Aging
PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis.2021Future Oncology
Evaluation of efficacy and safety of PARP inhibitors in breast cancer: a systematic review and meta-analysis.2021The Breast
Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2- negative metastatic or advanced breast cancer: a network meta-analysis.2021Aging
Poly (ADP-ribose) polymerase inhibitors in solid tumours: systematic review and meta-analysis.2021European Journal of Cancer

Clinical Practice Guidelines